Contribution of the vaccine to achievement of the national, regional or global disease goals

There are no established global elimination goals for Diphtheria or Pertussis (some countries have defined control goals for Diphtheria) 

The Maternal and Neonatal Tetanus Elimination (MNTE) initiative, launched by the World Health Organization (WHO) in 1989, initially aimed to eliminate neonatal tetanus by 1995. As of June 2024, 47 out of 59 priority countries have achieved MNTE status, significantly reducing neonatal tetanus cases by 89% and deaths by 84% since 2000. Vaccination is the cornerstone of the strategy. Immunizing women of reproductive age with tetanus toxoid-containing vaccines (TTCVs) has been the primary driver of this reduction. ,  

There is a clear and internationally recognized goal to eliminate hepatitis B as a public health threat. The World Health Organization (WHO) has set a target to achieve hepatitis B elimination by 2030, aiming for a 90% reduction in new infections and a 65% reduction in deaths. Vaccination is the single most important tool in the global effort to eliminate Hepatitis B. Widespread and timely hepatitis B vaccination, especially starting at birth, dramatically reduces new infections, chronic disease, and deaths from liver complications. The prevalence of hepatitis B surface antigen (HBsAg) in children under 5 dropped from 4.7% before vaccination to 1.3% by 2015, thanks to universal vaccination programs in 189 countries. , ,   

While no formal global Hib elimination goal is set by WHO, elimination of invasive Hib disease is considered biologically and programmatically possible, and has been achieved in some countries through high vaccination coverage. After the introduction of Hib conjugate vaccines, countries like the US, UK, and Canada saw a reduction in Hib disease incidence by over 95%, with some regions achieving near elimination of invasive Hib disease in children under five years old. More than 90% of countries have included Hib vaccines in their national immunization programs, resulting in significant global decreases in Hib disease, though complete eradication has not yet been achieved. ,  

Polio vaccination has reduced poliomyelitis cases by over 99.9% globally since the launch of the Global Polio Eradication Initiative in 1988. Coordinated immunization campaigns have led to the certification of polio-free status in the Americas (1994), the Western Pacific (2000), Europe (2002), and Africa (2020). Globally, the vaccines (Polio mono and multivalent and IPV-containing combination vaccines) have brought the world closer to eradicating wild poliovirus, which is now confined to Afghanistan and Pakistan. In addition, they play a critical role in controlling outbreaks of vaccine-derived poliovirus (cVDPV). , , , ,    

Sources

  • Maternal and neonatal tetanus elimination (MNTE). In: World Health Organization [website]. Geneva: World Health Organization; no date (https://www.who.int/initiatives/maternal-and-neonatal-tetanus-elimination-%28mnte%29, accessed 24 June 2025).

  • Jones CE, Yusuf N, Ahmed B, Kassogue M, Wasley A, Kanu FA (2024). Progress toward achieving and sustaining maternal and neonatal tetanus elimination — worldwide, 2000–2022. MMWR Morb Mortal Wkly Rep. 73:614–621. DOI: http://dx.doi.org/10.15585/mmwr.mm7328a1.

  • Chen D (2009). Hepatitis B vaccination: the key towards elimination and eradication of hepatitis B. J Hepatol. 50(4):805–816. https://doi.org/10.1016/j.jhep.2009.01.002.

  • Al-Busafi S, Alwassief A (2024). Global perspectives on the hepatitis B vaccination: challenges, achievements, and the road to elimination by 2030. Vaccines. 12. https://doi.org/10.3390/vaccines12030288.

  • Zhao H, Zhou X, Zhou Y (2020). Hepatitis B vaccine development and implementation. Hum Vaccin Immunother. 16:1533–1544. https://doi.org/10.1080/21645515.2020.1732166.

  • Slack M, Esposito S, Haas H, Mihályi A, Nissen M, Mukherjee P, Harrington L (2020). Haemophilus influenzae type b disease in the era of conjugate vaccines: critical factors for successful eradication. Expert Rev Vaccines. 19:903–917. https://doi.org/10.1080/14760584.2020.1825948.

  • Gilsdorf J (2021). Hib vaccines: their impact on Haemophilus influenzae type b disease. J Infect Dis. 224:S321–S330. https://doi.org/10.1093/infdis/jiaa537.

  • Frequently asked questions and considerations for the introduction of hexavalent vaccine DTwP-HepB-Hib-IPV in routine immunization programmes. In: World Health Organization [website]. Geneva: World Health Organization; 2024 (https://www.technet-21.org/en/resources/guidance/frequently-asked-questions-and-considerations-for-the-introduction-of-hexavalent-vaccine-dtwp-hepb-hib-ipv-in-routine-immunization-programmes-june-2024, accessed 24 June 2025).

  • World Health Organization (2022). Polio vaccines: WHO position paper – June 2022. Wkly Epidemiol Rec. 97(25):277–296. Available at: https://www.who.int/publications/m/item/polio-vaccines-who-position-paper-june-2022 (accessed 24 June 2025).

  • Global Polio Eradication Initiative website. In: Global Polio Eradication Initiative [website]. Geneva: Global Polio Eradication Initiative; no date (https://polioeradication.org/, accessed 24 June 2025).

  • Poliomyelitis: Fact sheet. In: World Health Organization [website]. Geneva: World Health Organization; no date (https://www.who.int/news-room/fact-sheets/detail/poliomyelitis, accessed 24 June 2025).

  • Poliomyelitis overview. In: Centers for Disease Control and Prevention [website]. Atlanta: CDC; no date (https://www.cdc.gov/polio/index.html, accessed 24 June 2025).